Innovent Biologics and Bolt Biotherapeutics collaborate to develop ISAC candidates Aug. 30, 2021 No Comments
RubrYc enters license and collaboration agreements on epitope-targeted antibody therapeutics Aug. 27, 2021 No Comments
Preclinical studies characterize bispecific EGFR/CD16A NK innate cell engager AFM-24 Aug. 27, 2021 No Comments
Phase I trial of molecular targeted therapy with adoptive cell therapy for DIPG and neuroblastoma Aug. 27, 2021 No Comments
Phase I study evaluates PGV-001-based personalized multipeptide vaccines for prostate cancer Aug. 27, 2021 No Comments
Memorial Sloan-Kettering Cancer Center describes prodrugs useful in adoptive cell therapy Aug. 26, 2021 No Comments
Coeptis Therapeutics and VyGen-Bio to codevelop products targeting CD38 cancers Aug. 20, 2021 No Comments
RSS